clinical trial · NCT04487080
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development, LLC·phase3·active not recruiting·n = 1,074
Carcinoma, Non-Small-Cell LungAmivantamabOsimertinibLazertinibPlacebo
brief summary
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
started
Sep 30, 2020
primary completion
Aug 11, 2023
completion
Nov 30, 2027
last updated
Jun 8, 2026
official title
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol